Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Molecular variants and mutations in medulloblastoma.

Schroeder K, Gururangan S.

Pharmgenomics Pers Med. 2014 Feb 4;7:43-51. doi: 10.2147/PGPM.S38698. eCollection 2014. Review.

2.

[Childhood medulloblastoma].

Yazigi-Rivard L, Masserot C, Lachenaud J, Diebold-Pressac I, Aprahamian A, Avran D, Doz F.

Arch Pediatr. 2008 Dec;15(12):1794-804. doi: 10.1016/j.arcped.2008.09.021. Epub 2008 Nov 7. Review. French.

PMID:
18995998
3.

Medulloblastoma molecular dissection: the way toward targeted therapy.

Remke M, Ramaswamy V, Taylor MD.

Curr Opin Oncol. 2013 Nov;25(6):674-81. doi: 10.1097/CCO.0000000000000008. Review.

PMID:
24076581
4.

Genetic and molecular alterations across medulloblastoma subgroups.

Skowron P, Ramaswamy V, Taylor MD.

J Mol Med (Berl). 2015 Oct;93(10):1075-84. doi: 10.1007/s00109-015-1333-8. Epub 2015 Sep 9. Review.

5.
6.

Genetics of medulloblastoma: clues for novel therapies.

Onvani S, Etame AB, Smith CA, Rutka JT.

Expert Rev Neurother. 2010 May;10(5):811-23. doi: 10.1586/ern.10.31. Review.

PMID:
20420498
7.

Subtle white matter volume differences in children treated for medulloblastoma with conventional or reduced dose craniospinal irradiation.

Reddick WE, Russell JM, Glass JO, Xiong X, Mulhern RK, Langston JW, Merchant TE, Kun LE, Gajjar A.

Magn Reson Imaging. 2000 Sep;18(7):787-93.

PMID:
11027871
8.

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.

Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM.

J Clin Oncol. 2011 Oct 10;29(29):3852-61. doi: 10.1200/JCO.2011.36.2798. Epub 2011 Sep 12.

PMID:
21911727
9.

New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology.

Brandes AA, Bartolotti M, Marucci G, Ghimenton C, Agati R, Fioravanti A, Mascarin M, Volpin L, Ammannati F, Masotto B, Gardiman MP, De Biase D, Tallini G, Crisi G, Bartolini S, Franceschi E.

Crit Rev Oncol Hematol. 2015 Jun;94(3):348-59. doi: 10.1016/j.critrevonc.2014.12.016. Epub 2014 Dec 31. Review.

PMID:
25600839
10.

[Medulloblastomas: review].

Taillandier L, Blonski M, Carrie C, Bernier V, Bonnetain F, Bourdeaut F, Thomas IC, Chastagner P, Dhermain F, Doz F, Frappaz D, Grill J, Guillevin R, Idbaih A, Jouvet A, Kerr C, Donadey FL, Padovani L, Pallud J, Sunyach MP.

Rev Neurol (Paris). 2011 May;167(5):431-48. doi: 10.1016/j.neurol.2011.01.014. Epub 2011 May 6. Review. French.

PMID:
21529869
11.

Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges.

Pollack IF.

J Neurosurg Pediatr. 2011 Aug;8(2):135-48. doi: 10.3171/2011.5.PEDS1178. Review.

PMID:
21806354
12.

Review of the prognostic factors in medulloblastoma of children and adults.

Brandes AA, Paris MK.

Crit Rev Oncol Hematol. 2004 May;50(2):121-8. Review.

PMID:
15157661
13.

The clinical implications of medulloblastoma subgroups.

Northcott PA, Korshunov A, Pfister SM, Taylor MD.

Nat Rev Neurol. 2012 May 8;8(6):340-51. doi: 10.1038/nrneurol.2012.78. Review.

PMID:
22565209
14.

Medulloblastoma comprises four distinct molecular variants.

Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD.

J Clin Oncol. 2011 Apr 10;29(11):1408-14. doi: 10.1200/JCO.2009.27.4324. Epub 2010 Sep 7.

15.

Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial.

Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, Michalski A, Campbell RH, Bailey CC, Thorp N, Pizer B, Punt J, Walker DA, Ellison DW, Machin D; Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee.

Eur J Cancer. 2010 Jan;46(1):120-33. doi: 10.1016/j.ejca.2009.09.013.

PMID:
19818598
16.

Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics.

Batora NV, Sturm D, Jones DT, Kool M, Pfister SM, Northcott PA.

Neuroscience. 2014 Apr 4;264:171-85. doi: 10.1016/j.neuroscience.2013.07.030. Epub 2013 Jul 20. Review.

PMID:
23876321
17.

Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.

Gupta T, Shirsat N, Jalali R.

Curr Pediatr Rev. 2015;11(2):106-19. Review.

PMID:
26133181
18.

Molecular diagnostics of CNS embryonal tumors.

Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD.

Acta Neuropathol. 2010 Nov;120(5):553-66. doi: 10.1007/s00401-010-0751-5. Epub 2010 Sep 30. Review.

19.

Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors.

Adamski J, Ramaswamy V, Huang A, Bouffet E.

F1000Prime Rep. 2014 Jul 8;6:56. doi: 10.12703/P6-56. eCollection 2014. Review.

20.

Medulloblastoma: what is the role of molecular genetics?

Entz-Werle N, Carli ED, Ducassou S, Legrain M, Grill J, Dufour C.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1169-81. doi: 10.1586/14737140.8.7.1169. Review.

PMID:
18588461

Supplemental Content

Support Center